Omalizumab is a recombinant humanized IgG1 monoclonal anti-IgE antibody used to treat allergic asthma and chronic urticaria. This activity will consider the indications, contraindications, mechanisms of action, adverse effects, and monitoring requirements of omalizumab; it will also provide an update on some of the key studies implemented with regards to asthma primarily and include urticarial reactions.

**Objectives:**
- Identify the mechanism of action of omalizumab.
- Describe the adverse effects of omalizumab.
- Outline the required monitoring and toxicity of omalizumab.
- Review interprofessional team strategies for improving care coordination and communication to advance the use of omalizumab and improve outcomes.